Isolated systolic hypertension: Primary care practice patterns in a Nigerian high-risk subpopulation

Sao Paulo Medical Journal

Volumn 124, Issue 2, 2006, Pages 105-109

  Ono, Agbani Ejaife ^a,c   Oyekigho, Erhun Wilson ^b   Adeleke, Ojo Araoye ^b  

^a NIGER DELTA UNIVERSITY   (Nigeria)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ambulatory blood pressure monitoring; Blood pressure; Hypertension; Primary health care; Systole

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; DIURETIC AGENT;

ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE FACILITY; HIGH RISK POPULATION; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL RECORD; MONOTHERAPY; NIGERIA; OUTPATIENT DEPARTMENT; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 33746890887     PISSN: 15163180     EISSN: 15163180     Source Type: Journal    
DOI: 10.1590/s1516-31802006000200011     Document Type: Review

References (26)

1. O'Rourke M, Frohlich ED. Pulse pressure: Is this a clinically useful risk factor? Hypertension. 1999;34(3):372-4.
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.
3. Simon AC, Safar MA, Levenson JA, Kheder AM, Levy BI. Systolic hypertension: hemodynamic mechanism and choice of antihypertensive treatment. Am J Cardiol. 1979;44(3):505-11.
4. Messerli FH. Essential hypertension in the elderly. Triangle. 1985;24:35-47.
5. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB, Frohlich ED. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet. 1983;2(8357):983-6.
6. Grassi G, Seravalle G, Bertinieri G, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens. 2000;18(5):587-93.
7. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157(21):2413-46.
8. 9 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension, Guidelines Subcommittee. J Hypertens. 1999;17(2):151-83.
9. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-64.
10. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64.
11. Cooper R, Rotimi C, Ataman S, et al. The prevalence of hypertension in seven populations of west African origin. Am J Public Health. 1997;87(2):160-8.
12. Bovet P, Ross AG, Gervasoni JP, et al. Distribution of blood pressure, body mass index and smoking habits in the urban population of Dar es Salaam, Tanzania, and associations with socieconomic status. Int J Epidemiol. 2002;31(1):240-7.
13. Cappuccio FP, Micah FB, Emmett L, et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension. 2004;43(5):1017-22.
14. Erhun WO, Olayiwola G, Agbani EO, Omotosho NS. Prevalence of Hypertension in a University Community in South West Nigeria. African Journal of Biomedical Research. 2005;8(1):15-9. Available from URL: http://www.bioline.org. br/abstract?id=md05002&lang=en. Accessed in 2006 (Jan 27).
15. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens. 1990;8(5):393-405.
16. Himmelmann A, Hedner T, Hansson L, O'Donnell CJ, Levy D. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Pressure. 1998;7(4):197-207.
17. Kannel WB, Dawber TR, McGee DL. Perspectives on systolic hypertension. The Framingham study. Circulation. 1980:61(6):1179-82.
18. Curb JD, Borhani NO, Entwisle G, et al. Isolated systolic hypertension in 14 communities. Am J Epidemiol. 1985;121(3):362-70.
19. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152(1):56-64.
20. Black HR. Individualized selection of antihypertensive drug therapy for older patients. Am J Hypertens 1998;11(3 Pt 2):62S-7S.
21. Hoesen WF, Beltman FW, May JF, et al. High prevalence of concentric remodeling in elderly individuals with isolated systolic hypertension from a population survey. Hypertension. 1997;29(2):539-43.
22. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345-52.
23. Hyman DJ, Pavlik VN, Vallbona C. Physician Role in Lack of Awareness and Control of Hypertension. J Clin Hypertens (Greenwich). 2000;2(5):324-30.
24. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-63.
25. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-44.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97.